MARX Biotech Co (ROCO:7731) PE Ratio: 60.88 (As of Jul. 17, 2026) — 15% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7731 MARX Biotech Co Ltd ROCO:7731
10 GF Score
Price NT$4.87
! 4 Warning Signs
View Full Analysis

What is MARX Biotech Co PE Ratio?

MARX Biotech Co ROCO:7731 -3.18% 10 PE Ratio is 60.88 as of Jul. 17, 2026, which is 15% below its 10-year median of 71.88. GuruFocus rates ROCO:7731 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-17), MARX Biotech Co's share price is NT$4.87. MARX Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08. Therefore, MARX Biotech Co's PE Ratio for today is 60.88.

During the past 6 years, MARX Biotech Co's highest PE Ratio was 89.88. The lowest was 52.25. And the median was 71.88.

MARX Biotech Co's EPS (Diluted) for the six months ended in Dec. 2025 was NT$0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.

As of today (2026-07-17), MARX Biotech Co's share price is NT$4.87. MARX Biotech Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08. Therefore, MARX Biotech Co's PE Ratio without NRI ratio for today is 59.39.

During the past 6 years, MARX Biotech Co's highest PE Ratio without NRI was 85.60. The lowest was 49.76. And the median was 68.46.

MARX Biotech Co's EPS without NRI for the six months ended in Dec. 2025 was NT$0.17. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.

During the past 3 years, the average EPS without NRI Growth Rate was 91.30% per year.

During the past 6 years, MARX Biotech Co's highest 3-Year average EPS without NRI Growth Rate was 91.30% per year. The lowest was 91.30% per year. And the median was 91.30% per year.

MARX Biotech Co's EPS (Basic) for the six months ended in Dec. 2025 was NT$0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.08.

Back to Basics: PE Ratio


MARX Biotech Co  (ROCO:7731) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


MARX Biotech Co PE Ratio Related Terms


MARX Biotech Co PE Ratio Historical Data

* Premium members only.

The historical data trend for MARX Biotech Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co PE Ratio Chart

MARX Biotech Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial N/A N/A N/A At Loss 59.63

MARX Biotech Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A At Loss At Loss At Loss 59.63

MARX Biotech Co PE Ratio Competitor Comparison

For the Pharmaceutical Retailers subindustry, MARX Biotech Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MARX Biotech Co PE Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where MARX Biotech Co's PE Ratio falls into.


ROCO:7731
10GF Score
MARX Biotech Co Ltd ROCO:7731
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MARX Biotech Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

MARX Biotech Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=4.87/0.080
=60.88

MARX Biotech Co's Share Price of today is NT$4.87.
For company reported semi-annually, MARX Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.08.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 60.88 mean?
MARX Biotech Co (ROCO:7731) has a PE Ratio of 60.88 as of Jul. 17, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on MARX Biotech Co and its competitors. This is 15% below median its historical median of 71.88. Over the past decade, MARX Biotech Co's PE Ratio has ranged from 52.25 to 89.88.
Is MARX Biotech Co's PE Ratio too high?
MARX Biotech Co's current PE Ratio of 60.88 is 15% below median its 10-year median of 71.88. Over the past 10 years, this metric has ranged from a low of 52.25 to a high of 89.88. Overall, MARX Biotech Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's PE Ratio compare to competitors?
MARX Biotech Co's PE Ratio of 60.88 can be compared against companies in the Healthcare Providers & Services industry. Historically, MARX Biotech Co's own PE Ratio has ranged from 52.25 to 89.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Healthcare Providers & Services company?
A good PE Ratio depends on the Healthcare Providers & Services industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on MARX Biotech Co and its competitors. MARX Biotech Co's current PE Ratio is 60.88, which is 15% below median its own 10-year median of 71.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current PE Ratio of 60.88. The current PE Ratio is 60.88, which is 15% below median its 10-year median of 71.88. MARX Biotech Co's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current PE Ratio is 60.88 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MARX Biotech Co Business Description

Address 5th Floor, No. 655, Bannan Road, Zhonghe district, New Taipei, TWN
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
10GF Score

Get the complete analysis for ROCO:7731

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$4.87
Price